Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast

Citation
C. Jones et al., Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast, AM J PATH, 158(1), 2001, pp. 207-214
Citations number
40
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
AMERICAN JOURNAL OF PATHOLOGY
ISSN journal
00029440 → ACNP
Volume
158
Issue
1
Year of publication
2001
Pages
207 - 214
Database
ISI
SICI code
0002-9440(200101)158:1<207:MCCOAH>2.0.ZU;2-H
Abstract
The relationship of apocrine metaplasia to invasive breast cancer is contro versial. Different authors have reported that apocrine differentiation in p roliferative lesions may be a risk factor, a precursor lesion, or have no a ssociation with malignancy. The aim of this study was to compare the geneti c alterations in benign apocrine hyperplasia with apocrine ductal carcinoma in situ (DCIS) and invasive apocrine carcinomas of the breast using compar ative genomic hybridization, The mean number of alterations in apocrine hyp erplasia was 4.1 (n = 10) compared to 10.2 in apocrine DCIS (n = 10) and 14 .8 (n = 4) in invasive carcinoma The most common alterations in apocrine hy perplasia were gains of 2q, 13q, and 1p and losses of 1p, 17q, 22q, 2p, 10q , and 16q, Apocrine DCIS and invasive carcinomas showed gains of 1q, 2q, 1p , and losses of 1p, 22q, 17q, 12q, and 16q as their most common DNA copy nu mber changes. Apocrine hyperplasia is considered to be a benign lesion and its relationship to invasive carcinoma remains unclear, Our data suggest th at some apocrine hyperplasias may be clonal proliferations. The mean number of alterations are lower in apocrine hyperplasia, however the changes show considerable overlap with those identified in in situ and invasive apocrin e carcinoma. These alterations are also commonly seen in nonapocrine breast cancer. The data are consistent with apocrine hyperplasia as a putative no nobligate precursor of apocrine carcinoma.